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Current estimates suggest that the number of HN-infected
people in South Africa will soon reach approximately 3 million,
with 1 600 new cases per day (90% of whom are unaware of
their infection).\
Medical scheme cover is still unavailable to the majority of
people in the private sector. Until recently, medical schemes
have tackled the problem by studiously avoiding the issue.
They have either excluded cover for HN/ AJDS.irelated
diagnoses, or imposed inadequate benefits. These benefits are
often not used, because of the lack of associated confidentiality
and because they are insufficient to cover the
cost of effective antifetroviral therapy. _
By excluding,or restricting b~nefits,ftedical
schemes havefow created an untenable
situation for themselves. Irrespective of this
policy, they are paying for un~osed HIV-related illnesses
and hospitalisation. As the number of HIV-infected
beneficiaries rises, schemes will be faced with massive
Or John Cowlin has pioneered benefit manageme~t in
South Africa. He in~oduced the splitting of medital
benefits into chronic and routine. He fought through
uncharted territory in order to do this but emerged
relatively unscathed! Under his leadership the first chronic
medication programme in South Africa was introduced,
followed by the Aid for AIDS programme. As Executive
Chairman of PBM (Pty) Ltd and board member of
Medscheme he plays an influential role in South African
health care. Laubi Walters is growing old, but remains
committed to translating the principles of clinical
pharmacology into everyday practice. As Clinical Director,
he is responsible for the clinical standards of PBM (Pty)
Ltd's programmes and is the project leader for Aid for
AIDS. In the role of senior medical advisor, Or Lean
Regensberg talks to the medical profession on a daily basis.
His primary task is to balance the unforgiving evidence-
based approach with pragmatism. Guy Ramsay is a young
scientist who by means of sifting evidence delivers clear
and succinct solutions which often astound the three
clinicians.
unmanaged costs with potentially catastrophic implications for
all their members. The situation is worsened by a lack of
accurate data on the extent of the problem within individual
schemes.
With these issues in mind, Pharmaceutical Benefit
Management (Pty) Ltd (PBM) has developed a comprehensive
programme ('Aid for AIDS') to allow for reimburseme.ilt of all
aspects of treatment of HIV/ AIDS. Its aim is to facilitate
clinical and financial management of HIV infection and to
reimburse the most cost-effective and appropriate therapy,
within the available budget, for beneficiaries of client schemes.
The management of HIV infection/AIDS presents unique
challenges. These include exciting new therapeutic approaches,
newly extended life expectancy, difficulties in predicting the
real costs of care, the wide variety of services which may be
required during the course of the disease, and confidentiality.
Dynamic consensus guidelines are essential for the informed
decision making necessary to meet these challenges. The 'Aid
for AIDS' (AfA) guidelines were developed following extensive
discussions with local consultants as well as medical
practitioners throughout the country. The first edition has been
circulated as a discussion document to the
majority of practising doctors in South
Africa who are involved in treating people
living with HIV/ AIDS. As this document
forms the basis of the AfA programme, it
has to be scientifically and ethically sound. Every effort will be
made to ensure that this continues in future.
There is no doubt that recent declines in morbidity and
mortality due to.HIV infection are attributable to the use of
potent new antiretroviral regimens.' Internationally accepted
guidelines recognise the optimal treatment of HIV infection as
being a triple combination of two nucleoside reverse
transcriptase inhibitors and a protease inhibitor (highly active
antiretroviral therapy or HAART).3 The combination is usually
initiated when the CD4 count has dropped to below 500
cells/plo However, judicious financial modelling indicated that
medical schemes would not always be able to afford this ideal
approach.
Currently, therefore, three levels of access to payment for
antiretroviral therapy are provided for by the AfA programme:
level 1 - prevention of vertical transmission; level 2 - dual
nucleoside reverse transcriptase inhibitors; and level 3 -
conventional triple therapy. It is anticipated that levell would
cLways be combined with either level 2 or level 3. Currently,
dual and triple therapy would only be approved for payment
when the CD4 count falls to below 350 cells/j.l1. All patients
have access to therapy for both minor HIV-related conditions
and AIDS-defining conditions and hospitalisation, and funding
is also provided for immunisation, prophylactic medication
(e.g. co-trimoxazole) and appropriate investigations needed to






The principle of 'event-driven benefits' underpins the AfA
programme. This unique concept links defined biological and
pathological events to specific treatment programmes. The
occurrence of such an event in the patient's illness will make
available the benefits to fund the approved treatment protocol.
The AfA programme therefore depends on co-<Jperation from
the responsible medical practitioner to notify the programme
once an event has occurred, otherwise the benefit cannot be
made available. Pre-authorisation is only required for
hospitalisation and certain very costly investigations and
therapies, and this has been kept to a minimum to limit the
administrative burden on providers of care.
The issue of confidentiality has been addressed by creating a
restricted access administrative unit with a dedicated computer
and communication system. Provided patients, doctors,
pharmacists and hospitals deal directly with the unit, HIV-
positive beneficiaries cannot be identified by the employer, the
medical scheme or the administrator. Secure toll-free fax and
phone lines are available for medical practitioners, and a
dedicated nurseIine is available for use b~membersenrolled
\ on the programme to a~ist with queries ~d enhance
compliance with prescribed treatment This has been identified
as a major factor iii the effectiveness of antiretroviral therapy.
AfA has no interests in the buying, distribution or selling
of medicines. It will, however, wo!"k closely with the .
pharmaceutical industry in orderl~Jeduce the cost of
expensive antiretroviral therapy ~Ci other drugs used in the
treatment of opportunistic infections. Encouraging
developments have already occurred in this regard. These will
benefit persons who are not members of medical schemes as
well. Co-<Jperation with academic institutions and professional
organisations, as well as other interest groups, is being
explored. The programme also offers opportunity for research
and the development of an Afrocentric approach to the
treatment of HIV/ AIDS in South Africa.
While accepting certain financial realities, the AfA
programme represents a significant advance in the provision of
care and availability of benefits to the majority of previously
disadvantaged medical scheme members and their dependants
who are living with HIV infection and AIDS.
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CONFRONTING AIDS - A PLEA
FOR A NATIONAL DRIED MILK
FORMULA
DLWoods
The threat of AIDS is rapidly spreading across South Africa,
and few are at greater risk of infection than babies born to HIV-
positive women. The risk of vertical transmission of HIV from
mother to infant is approximately 35% in South African
populations where breast-feeding is commonly practised. It has
been estimated that up to half of perinatal transmission may
occur via breast-milk. As a result, many HIV-infected mothers
are advised not to breast-feed their infants. While this practice
is widely accepted in affluent countries, it must be viewed with
caution in poor communities where undernutrition and gastro-
enteritis remain common causes of infant mortality.
The recent worldwide attempts to promote exclusive breast-
feeding of newborn infants, especially in developing countries,
hi!ve received much support in South Africa, with the
implementation of the ten steps to successful breast-feeding
and the baby-friendly hospital initiative. The slogan 'breast is
best' is often heard, and posters promoting the many
advantages of breast-feeding are prominently displayed in
antenatal clinics. Will all that has been achieved by these
p~es simply be swept away by the AIDS epidemic?
The argument for giving dried milk formulas to newborn
infants at risk of HIV infection is convincing. Furthermore,
many health care organisations, such as the World Health
Organisation, suggest that HIV-infected women who can afford
to buy milk formula should be discouraged from breast-
feeding. Where does this approach leave the woman who is
unable to afford milk formula, or the State, which may not be
able to provide free or subsidised formula to these infants? An
innovative scheme to bring the cost of milk formula within the
reach of most HIV-infected mothers is needed.
A cheap national dried milk formula was introduced into the
UK very successfully. A similar scheme could be launched in
South Africa. Contracts could be issued on a competitive basis
to the private sector for the manufacture of a suitable milk
formula which should meet the basic nutritional needs of
normal infants. A further reduction in cost could be achieved
by packaging the formula in sachets rather than ~. The
packaging would carry no commercial name or advertising,
but simply give the contents as South African national i.Lfant
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